Hong Kong biotech shares rally on expanding mRNA cancer vaccine pipelines
Shares of Hong Kong-listed biotechnology firms are surging as domestic companies rapidly expand their pipelines of personalised mRNA cancer vaccines following a major clinical breakthrough by Moderna and Merck.
Hong Kong-listed biotechnology companies are experiencing significant stock price increases following a major clinical milestone for mRNA cancer treatments. The market rally was triggered by the announcement that a personalised mRNA vaccine developed by Moderna and Merck successfully reduced the risk of melanoma recurrence in a late-stage trial.
The phase three trial, which included approximately 1,140 patients, marked the first time an mRNA cancer vaccine demonstrated such efficacy in preventing the disease from returning or spreading. This breakthrough sparked strong investor enthusiasm for the next wave of biotechnology innovation and potential commercial returns.
Domestic firms are capitalising on the momentum by accelerating their own research and development efforts to capture future market share. Companies ranging from Jiangsu Hengrui Pharmaceuticals to Li Ka-shing-backed CK Life Sciences already maintain extensive portfolios of cancer vaccines in various stages of development.
The commercial opportunity for these therapies is substantial within the region, providing a strong financial incentive for corporate investment. China records nearly 2.6 million cancer-related deaths annually, presenting a massive addressable market for any firm that can successfully bring a viable treatment to patients.
“China is moving quickly and has already built a large pipeline of more than 100 cancer vaccine programmes,” said Cui Cui, head of healthcare research for Asia at Jefferies. This rapid expansion indicates a strategic pivot by domestic developers toward highly specialised oncology treatments to meet local demand.
Despite the current market enthusiasm and surging share prices, significant operational hurdles remain for these biotechnology firms. It is currently unknown whether these companies possess the capability to manufacture personalised vaccines rapidly and at a commercially viable cost, according to the Jefferies analyst.
Investors will be watching closely to see if these domestic pipelines can translate clinical ambition into scalable, profitable manufacturing. The coming quarters will test whether the current stock valuations are justified by tangible product development and eventual regulatory approvals.
